{"id":15585,"date":"2018-05-28T18:27:11","date_gmt":"2018-05-28T18:27:11","guid":{"rendered":"https:\/\/mann.vamtam.com\/?page_id=15585"},"modified":"2021-11-25T14:07:10","modified_gmt":"2021-11-25T14:07:10","slug":"irdd-speakers","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/","title":{"rendered":"Inhalation & Respiratory Drug Delivery 2021 Speakers"},"content":{"rendered":"
\n

\n\tOur
Speakers (A-Z)\n\t<\/h2>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tAernout van Haarst\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Director, Scientific Affairs at Celerion<\/h5>\n

\n\t\t\t\n\tEarly Phase Clinical Trials for Inhaled Drugs – Challenges and Opportunities\n\t\t\t<\/a>\n\t<\/h3>\n\t

As Director, Scientific Affairs, Dr. Aernout van Haarst plays a key role in leveraging Celerion’s scientific and drug development expertise to support drug development programs of Celerion’s clients. He is a member of Celerion’s respiratory and vaccine research teams and is the scientific liaison to various external experts in the fields of pulmonology and vaccine development.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tAnna Sipitanou\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Business Development Manager at Copley Scientific<\/h5>\n

\n\t\t\t\n\tIVIVC testing for OINDP products – Bridging the gap and accelerating product to market journey\n\t\t\t<\/a>\n\t<\/h3>\n\t

Anna Sipitanou is the Business Development Manager for Copley Scientific. She holds a BSc in Chemistry and an MSc in Drug Discovery & Pharmaceutical Sciences. Having joined Copley Scientific in 2017, Anna plays a key role in the company’s technical and sales support services, including the training of customers on a wide range of pharmaceutical testing equipment, with a particular focus on OINPD testing.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tArkadiusz Kuczaj\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Manager Aerosol Research and Dosimetry at Philip Morris International Research and Development<\/h5>\n

\n\t\t\t\n\tAccurate dosimetry predictions for evolving liquid aerosol delivery\n\t\t\t<\/a>\n\t<\/h3>\n\t

Arkadiusz K. Kuczaj earned his PhD (2006) in the field of Applied Mathematics from the University of Twente, the Netherlands. As Manager of Aerosol Research and Dosimetry, he is currently leading aerosol delivery and characterization, in vitro exposure, and in vivo inhalation research in the Biomedical Research Department (BMRD) at Philip Morris International R&D (PMI R&D) in Neuchatel, Switzerland.<\/p>\n

He published and co-authored more than 30 technical manuscripts in the field of life-science, aerosol research, computational physics and fluid dynamics.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tBeatriz Noriega Fernandes\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Scientist, Formulation Group – Drug Product Development at Hovione<\/h5>\n

\n\t\t\t\n\tHigh Dosage DPI – formulation and process development considerations\n\t\t\t<\/a>\n\t<\/h3>\n\t

Beatriz Noriega Fernandes holds a MSc Degree in Biological Engineering by Instituto Superior T\u00e9cnico, University of Lisbon, 2015.<\/p>\n

She joined Hovione in the same year as an Industrial PhD Candidate in collaboration with Faculty of Pharmacy, University of Lisbon, specializing in dissolution methodologies and in vivo\/in vitro correlations for dry powder inhaler formulations.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tBernhard M\u00fcllinger\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
General Manager, Chief Operating Officer at Resyca<\/h5>\n

\n\t\t\t\n\tBiologics Delivered in Liquid Form by Soft-Mist-Inhalers (SMI)\n\t\t\t<\/a>\n\t<\/h3>\n\t

Bernhard M\u00fcllinger is Chief Operating Officer General Manager at Resyca. With the resyca team he provides seamless outsourcing services for drug-device combination products in liquid formulations.\u00a0He has worked on smart nebuliser devices and has extensive experience in medical device development and clinical development of combination products. Before joining Resyca Bernhard has worked at Vectura, Activaero, Inamed-CRO, at the Asklepios Clinic and at the Helmholtz-Zentrum.<\/p>\n\t\t\t\t\t\t\t\"\"\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tDavid Wyatt\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Chief Operating Officer at Aston Particle Technologie<\/h5>\n

\n\t\t\t\n\tThe development and supply of respiratory medicines\n\t\t\t<\/a>\n\t<\/h3>\n\t

David is a physical chemist (holding a PhD in Surface Chemistry and Colloid Science) with extensive medicine development experience. He spent 32 years with GlaxoSmithKline, in a range of increasingly senior scientific and management positions both in Research and Development and in Manufacturing. During that time, he and his teams assisted in the development of 5 respiratory medicines from molecule selection to be amongst today’s gold standard treatments for asthma and chronic obstructive pulmonary disease.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tFelix Weiland\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Head of Product & Process Technology at Boehringer Ingelheim<\/h5>\n

\n\t\t\t\n\tAre Sustainability, Reusability and Carbon Neutrality Major Trends for Devices in the Future?\n\t\t\t<\/a>\n\t<\/h3>\n\t

Felix is a pharmacist by training with a PhD in pharmacology. In 2006, he joined Boehringer Ingelheim as a trainee, focusing on launch and transfer activities of inhalative products. He then took over different roles at BI microParts in Dortmund at the development site of inhalation devices as development QA manager, senior project manager, and lab head of device development.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tHugo Almeida\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
International Business Development Consultant at AdAlvo (an Alvogen subsidiary)<\/h5>\n

\n\t\t\t\n\tInhalation and Nasal routes as stairways to drug Innovation\n\t\t\t<\/a>\n\t<\/h3>\n\t

Business Development professional with a background in Pharmaceutical Sciences. Over 12 years of experience acquired in Business Development (pipeline and portfolio management), Quality and Operations, and R&D, in Pharma Industry and Academia. Most relevant experience includes building an internal pipeline of 505b2 and generic products in Ophthalmology, Dermatology and Respiratory fields.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tJeffry Weers\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Chief Technical Officer at cystetic Medicines, Inc.<\/h5>\n

\n\t\t\t\n\tMusings on High Dose Powder Delivery\n\t\t\t<\/a>\n\t<\/h3>\n\t

Jeffry Weers is currently the Chief Technical Officer at Respira Therapeutics, Inc. He holds a B.S. degree in Chemistry from the University of Puget Sound (1980), and a Ph.D. in Physical Chemistry from the University of California, Davis (1985).<\/p>\n

Previously, Jeff was the Chief Scientific Officer for Respiratory at Novartis Pharmaceuticals Corporation (2009-2017). \u00a0Prior to joining Novartis, Jeff spent roughly a decade (1999-2008) with Nektar Therapeutics (formerly Inhale Therapeutic Systems), where he held various positions within the Research and Development organization.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tJ\u00f6rg Schiewe\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Head of Global CMC Experts at Boehringer Ingelheim Pharma GmbH & Co. KG<\/h5>\n

\n\t\t\t\n\tScience base and challenges of therapeutic equivalence of respiratory products.\n\t\t\t<\/a>\n\t<\/h3>\n\tDr J\u00f6rg Schiewe is the Head of Global CMC Experts at Boehringer Ingelheim Pharma GmbH & Co. KG, Germany.
\nHe studied chemistry at the Martin-Luther-University in Halle, Germany and earned his PhD in the field of physical chemistry in 1994. The Alexander von Humboldt foundation awarded Dr. Schiewe a Feodor-Lynen-Fellowship to perform post-doctoral work with Prof. Alan Bond at Monash University in Melbourne, Australia (1995-1997).\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tMarco Laackmann\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Director Inhalation Technology at Harro H\u00f6fliger<\/h5>\n

\n\t\t\t\n\tGet it right first time: Inhaler technology and manufacturing\n\t\t\t<\/a>\n\t<\/h3>\n\t

Marco Laackmann has an Engineering degree in Chemical Engineering applied Biotechnology from University of Applied Science Emden in Germany and a MBA from Bradford School of Management in UK.<\/p>\n

His background includes 15 years of experience in various areas of Dry Powder Inhaler covering aspects of device development, manufacturing and quality control of medical devices as well as powder dosing technologies and process development.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tMark Milton-Edwards\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Head of Product & Health Solutions – Digital Health at Teva Pharmaceuticals<\/h5>\n

\n\t\t\t\n\tDigital Pharmaceuticals: A case study\n\t\t\t<\/a>\n\t<\/h3>\n\t

Mark has worked with Swellaway Ltd. for >3yrs. in a NED role with a special focus on Digital Health Regulatory, IP and commercialisation. Mark holds a full-time role for more than 13yrs with TEVA Pharmaceuticals and over 16years with AstraZeneca prior to this. Mark has held various positions including R&D Project Leader, VP Sales & Marketing, Strategic Planning & Business Development, and Global Brand Lead. Graduated in Aeronautical Sciences and completed his MBA at Durham University, UK.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tMarkus Mezger\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
CEO at Mematec solutions<\/h5>\n

\n\t\t\t\n\tMDPI for 2 API\n\t\t\t<\/a>\n\t<\/h3>\n\t

Since 1994 working in the Pharma Industrie 7 years at Robert Bosch GmbH as head of product management and technical director for capsule, blister, antibiotica,- filling machines. founding 2001 at mematec consulting, here mainly worked for Companies as Harro Hoefliger to design capsule filling equipment and filling equipment for inhalers, Rohwedder GmbH to design assembly machines for medical and Pharma application.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tMartin Wing-King\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Director of Project Management at Quotient Sciences<\/h5>\n

\n\t\t\t\n\tFormulation Development Challenges and Pitfalls When Developing Dry Powder Inhalers\n\t\t\t<\/a>\n\t<\/h3>\n\t

Martin Wing-King is the Director of Project Management at Quotient Sciences’ Reading, UK facility. Martin began his career in Analytical Development at Johnson Matthey, and over the course of 8 \u00bd years transitioned from the lab into a sales role within the company.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tMichael Tauber\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Senior Director of Pharmaceutical Development and Technical Operations at Acorda Therapeutics<\/h5>\n

\n\t\t\t\n\tARCUS\u00ae: Engineered Spray Dried Particles for Inhalation Delivery\n\t\t\t<\/a>\n\t<\/h3>\n\t

Michael Tauber is Senior Director of Pharmaceutical Development and Technical Operations at Acorda Therapeutics. Since 2002, he has worked in various areas of pharmaceutical development including early and late stage development, pre-formulation and formulation for solid oral development, formulation and scale up of spray dried engineered particles for inhalation delivery and management of CMC related activities supporting the development and commercialization of Inbrija\u00ae<\/sup>.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tN\u00e9lio Drumond\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Senior Principal Scientist at Takeda Pharmaceuticals<\/h5>\n

\n\t\t\t\n\tTitle: Towards development of patient-centric inhalers: Leveraging human factors, inhalation device and formulation science\n\t\t\t<\/a>\n\t<\/h3>\n\t

N\u00e9lio Drumond is a PharmD by training with a PhD in Patient Centric Drug Product Design. He shares several years of experience in the Pharmaceutical Industry providing scientific leadership to govern the formulation and manufacturing aspects of drug product development projects during clinical stages, including their subsequent scalability and validation for commercial use.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tNuria Roldan\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Project Leader at AlveoliX<\/h5>\n

\n\t\t\t\n\tA lung-on-chip approach towards predictive in vitro inhalation\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr. Roldan works as lead scientist and project manager at AlveoliX since 2019. Currently, she is responsible for the development and implementation of microphysiological system\/organ-on-chip approaches for early- and late-phase drug development. Her research involves generating human models of the distal airways that can be used for safety and efficacy testing, as well as for inhalation toxicology.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tPaul Johnson\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Managing Director at Paul Johnson Consulting Limited<\/h5>\n

\n\t\t\t\n\tUnmet Needs and Future Trends in Respiratory Drug Delivery\n\t\t\t<\/a>\n\t<\/h3>\n\t

Paul Johnson is an independant consultant specialising in the pharmaceutical development of inhalation drug delivery systems. He has provided consultancy services to both NCE and generic drug development companies since 2018. Prior to this Paul gained 20 years of experience in leading the CMC aspects of much of GSK’s respiratory portfolio, including leading Relvar Ellipta from early research to registration, launch and lifecycle management.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tPeter Robbins\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Professor of Physiology at the University of Oxford<\/h5>\n

\n\t\t\t\n\tOptimising surrogate outcome measures for respiratory trials\n\t\t\t<\/a>\n\t<\/h3>\n\t

Peter Robbins is Professor of Physiology at the University of Oxford. He has a strong reputation for developing innovative technologies to address previously intractable questions in human physiology, particularly relating to respiratory and cardiovascular function. His interests include hypoxia biology and iron homeostasis. In these areas, he has had a long-term collaboration with Professor Sir Peter Ratcliffe, the 2019 Nobel Laureate in Physiology or Medicine.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tSven Stegemann\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Professor of patient centric drug design and manufacturing at the Graz University of Technology, Austria<\/h5>\n

\n\t\t\t\n\tIncreasing the drug load in capsule based DPI drug delivery systems\n\t\t\t<\/a>\n\t<\/h3>\n\t

Prof. Dr. Sven Stegemann is professor of patient centric drug design and manufacturing at the Graz University of Technology, Austria. Over the course of his 27-year career in the pharmaceutical industry, he has worked as an advisor to major pharmaceutical companies on ways to improve the design, development and manufacture of pharmaceutical products so they better address the individual needs of patients.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tThomas Secher\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Research scientist (CRCN) at INSERM<\/h5>\n

\n\t\t\t\n\tThe biological barriers to consider for the development of inhaled biotherapeutics\n\t\t\t<\/a>\n\t<\/h3>\n\t

Thomas is a research scientist in the field of mucosal immunology and therapeutics. He is particularly concerned about infectious diseases and the way we can prevent them. Quickly realized the importance of the host-pathogen-environment triad in determining the outcome of infectious events and he was fascinated by the host-pathogen dualism and how their interactions dictate pathogenesis and subsequently modulate the efficacy of therapeutics. Studying this in more details has always been the driving force of my research.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tTonya Winders\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
President and Chief Executive Officer of Allergy & Asthma Network<\/h5>\n

\n\t\t\t\n\tShared Decision Making to Improve Adherence in Severe Asthma\n\t\t\t<\/a>\n\t<\/h3>\n\t

Tonya Winders. MBA is currently the President and Chief Executive Officer of Allergy & Asthma Network, the leading patient advocacy organization dedicated to ending the needless death and suffering due to asthma, allergies and related conditions.<\/p>\n

Tonya has over 17 years experience in leadership roles within the allergy and asthma industry. From sales and marketing leadership to managed markets access, she has worked tirelessly to ensure patients have access to effective diagnostic and treatment tools.<\/p>\n\n<\/div>","protected":false},"excerpt":{"rendered":"

Our Speakers (A-Z) Aernout van Haarst Director, Scientific Affairs at Celerion Early Phase Clinical Trials for Inhaled Drugs – Challenges and Opportunities As Director, Scientific Affairs, Dr. Aernout van Haarst plays a key role in leveraging Celerion’s scientific and drug development expertise to support drug development programs of Celerion’s clients. He is a member of…<\/p>\n","protected":false},"author":1,"featured_media":32257,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-15585","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"\nInhalation & Respiratory Drug Delivery 2021 Speakers • BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"The IRDD Stream is designed for senior industry experts that will showcase new trends in aerosol science and the future directions of inhalation drug delivery research. Further discussion focusses on the regulatory pathways for inhaled therapies and challenges of bringing respiratory products to market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Inhalation & Respiratory Drug Delivery 2021 Speakers • BioTech Pharma Summit\" \/>\n<meta property=\"og:description\" content=\"The IRDD Stream is designed for senior industry experts that will showcase new trends in aerosol science and the future directions of inhalation drug delivery research. Further discussion focusses on the regulatory pathways for inhaled therapies and challenges of bringing respiratory products to market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2021-11-25T14:07:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Background_Banner_Logo_BioTech_Pharma_Summit_Facebook.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"15 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/\",\"name\":\"Inhalation & Respiratory Drug Delivery 2021 Speakers • BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Background_Banner_Logo_BioTech_Pharma_Summit_Facebook.png\",\"datePublished\":\"2018-05-28T18:27:11+00:00\",\"dateModified\":\"2021-11-25T14:07:10+00:00\",\"description\":\"The IRDD Stream is designed for senior industry experts that will showcase new trends in aerosol science and the future directions of inhalation drug delivery research. Further discussion focusses on the regulatory pathways for inhaled therapies and challenges of bringing respiratory products to market.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/#primaryimage\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Background_Banner_Logo_BioTech_Pharma_Summit_Facebook.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Background_Banner_Logo_BioTech_Pharma_Summit_Facebook.png\",\"width\":1200,\"height\":630},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Inhalation & Respiratory Drug Delivery 2021 Speakers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow's healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Inhalation & Respiratory Drug Delivery 2021 Speakers • BioTech Pharma Summit","description":"The IRDD Stream is designed for senior industry experts that will showcase new trends in aerosol science and the future directions of inhalation drug delivery research. Further discussion focusses on the regulatory pathways for inhaled therapies and challenges of bringing respiratory products to market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/","og_locale":"en_US","og_type":"article","og_title":"Inhalation & Respiratory Drug Delivery 2021 Speakers • BioTech Pharma Summit","og_description":"The IRDD Stream is designed for senior industry experts that will showcase new trends in aerosol science and the future directions of inhalation drug delivery research. Further discussion focusses on the regulatory pathways for inhaled therapies and challenges of bringing respiratory products to market.","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2021-11-25T14:07:10+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Background_Banner_Logo_BioTech_Pharma_Summit_Facebook.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"15 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/","name":"Inhalation & Respiratory Drug Delivery 2021 Speakers • BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/#primaryimage"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Background_Banner_Logo_BioTech_Pharma_Summit_Facebook.png","datePublished":"2018-05-28T18:27:11+00:00","dateModified":"2021-11-25T14:07:10+00:00","description":"The IRDD Stream is designed for senior industry experts that will showcase new trends in aerosol science and the future directions of inhalation drug delivery research. Further discussion focusses on the regulatory pathways for inhaled therapies and challenges of bringing respiratory products to market.","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/#primaryimage","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Background_Banner_Logo_BioTech_Pharma_Summit_Facebook.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Background_Banner_Logo_BioTech_Pharma_Summit_Facebook.png","width":1200,"height":630},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"Inhalation & Respiratory Drug Delivery 2021 Speakers"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow's healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/15585","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=15585"}],"version-history":[{"count":79,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/15585\/revisions"}],"predecessor-version":[{"id":37244,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/15585\/revisions\/37244"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media\/32257"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=15585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}